what are you talking about? read the graphs I linked back to in my previous post to the P2 results diagrams. They showed the between group differences at different effect sizes which is what a good P2 trial does. how can you say a 50% effect size (improvement on VAS/ODI) is not clinically significant? the industry standard for CMWTE in health care is 10% that would be 0.5 or half a point on VAS? There was a significantly bigger group of patients in the experimental group that got a 50% improvement on VAS and ODI than controls, Like 42% compared to 16% or similar. yes you are talking RRR instead of ARR but who cares? drugs have been approved on 10% reductions in RR or less! There is no other Rx in class for CLBP and nothing works to fix it. If this Rx can reduce pain and ODI and stop or slow deterioration, it will be a license to print $. We will see.
MSB Price at posting:
$2.41 Sentiment: Buy Disclosure: Held
(20min delay)